top of page

NEW combination trial arm of RMC-9805 plus RMC-6236

Changes to KRAS G12D trial - July 23, 2024

The monotherapy arm of RMC-9805 - RAS(ON) inhibitor

now includes info on the combination arm of RMC-9805 plus RMC-6236

 

Expansion to 17 US trial sites

290 to 444 patients

 

NCT06040541 trial listing

 

Study of RMC-9805 in Participants With KRASG12D-Mutant Solid Tumors

"This is an open-label, multicenter, Phase 1/1b study of RMC-9805, monotherapy, selective and orally bioavailable KRAS G12D(ON) inhibitor, in subjects with KRASG12D-mutant solid tumors to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary clinical activity. The study consists of two parts: Part 1- Dose-Exploration and Part 2- Dose-Expansion."

 

Phase 1 trial from Revolution Medicines, Inc.

Opened in September 2023, Enrolling in the US

  • Colorectal Cancer (CRC)

  • Advanced Solid Tumors (this would include Appendiceal)

 

Contact info


NOTE: All interventional trials involve risk, so please discuss with your oncology team. And ask questions of the researchers e.g. patient responses and any side effects on treatment.


Revolution Medicines - scientific presentation, May 2023

RAS(ON) Inhibitors - RMC-9805 (KRASG12D) - slides 18 – 22 (slide 18 pictured)

 

 

 

 

May 2024 - Revolution Medicines press release

“Expanding the reach of RMC-6236 monotherapy and/or combination regimens into earlier lines of therapy, RAS cancer genotypes beyond RAS G12X, and tumor types beyond NSCLC and PDAC. Objective responses have been observed in second and later line monotherapy treatment of patients with a range of solid tumor types carrying diverse RAS mutation variants. Exploratory clinical studies of several combinations have been initiated to inform potential options for studies in the first line (1L) treatment of metastatic or earlier stage cancers. “

 






 

 

This website is not intended to, and does not, provide medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

© 2025 KRAS Cancer Connect. All rights reserved.    Nonprofit EIN 85-4372947 

bottom of page